1. Scrip

Where Will CNS Drug Development Go In 2018?

 
• By Lucie Ellis-Taitt

The world's expanding, aging population means diseases of the central nervous system, like Alzheimer's and Parkinson's, are potential blockbuster areas for innovative pharma and biotech companies that are able to navigate clinical studies and get to market. Scrip looks at five emerging trends that are likely to affect the CNS drug development landscape in 2018.

GoldKeyInPuzzle_1200x675
Unlocking new opportunities: CNS field is poised for a breakthrough

Pharma and biotech drug developers have been targeting disorders affecting the central nervous system for decades but many conditions still have no effective treatments that target the root cause of disease, and the field continues to offer considerable opportunity.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas